Kamada (KMDA) Cash from Financing Activities (2013 - 2026)

Kamada (KMDA) posted quarterly Cash from Financing Activities of -$856000.0 for Q1 2026, down 192.15% year-on-year from $928918.5 in Q1 2025, and up 27.4% on a QoQ basis from -$1.2 million in Q4 2025.

Kamada (KMDA) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Kamada (KMDA) has reported Cash from Financing Activities for 14 consecutive years, with -$856000.0 the latest figure, recorded in Q1 2026.

  • Quarterly Cash from Financing Activities fell 192.15% year-over-year to -$856000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 123.37% YoY) and the FY2025 annual result came in at -$18.3 million, down 31.87% from the prior year.
  • Cash from Financing Activities climbed to -$856000.0 in Q1 2026 per KMDA's latest filing, from -$1.2 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for KMDA reached as high as $31.3 million in Q3 2023 and fell as low as -$16.1 million in Q2 2025.
  • A 5-year average of -$961184.8 and a median of -$1.6 million in 2023 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 1384222.07% — and 2024, when it slumped 199101.67%.
  • Year by year, Cash from Financing Activities stood at -$2.9 million in 2022, then surged by 44.93% to -$1.6 million in 2023, then surged by 55.22% to -$708000.0 in 2024, then slumped by 66.53% to -$1.2 million in 2025, then rose by 27.4% to -$856000.0 in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$856000.0, -$1.2 million, and -$754000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Kamada 401.22 Mn 328.07 Mn 19.12 Mn -856,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -856,000.00
Mar 31, 2026 -856,000.00
Dec 31, 2025 -1.18 Mn
Dec 31, 2025 -1.18 Mn
Sep 30, 2025 -754,000.00
Sep 30, 2025 -754,000.00
Jun 30, 2025 -16.12 Mn
Jun 30, 2025 -16.12 Mn
Mar 31, 2025 -293,000.00
Mar 31, 2025 -293,000.00
Dec 31, 2024 -708,000.00
Dec 31, 2024 -708,000.00
Sep 30, 2024 -4.79 Mn
Sep 30, 2024 -4.79 Mn
Jun 30, 2024 -2.68 Mn
Jun 30, 2024 -2.68 Mn
Mar 31, 2024 -5.74 Mn
Mar 31, 2024 -5.74 Mn
Dec 31, 2023 -1.58 Mn
Dec 31, 2023 -1.58 Mn